7 completed, 1 active not recruiting. 8 Phase 1, 1 Phase 2.
By phase and status
Follow Glabellar Lines: new trials by email Literature Review of Glabellar Lines trials Research Report on Glabellar Lines
Trials (filtered) newest first · largest first
All 8 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar Lines
AGN-151586, BOTOX - Glabellar Lines | Phase 1 | Active not recruiting | 143 | 2026-08-10 | 2026-11-02 |
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)
AGN-151586, OnabotulinumtoxinA, Placebo - Glabellar Lines | Phase 1 | Completed | 132 | 2025-02-18 | 2025-11-17 |
Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines
DWP712, BOTOX® - Glabellar Lines | Phase 1 | Completed | 20 | 2023-11-28 | 2024-04-04 |
A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines
AGN-151586, BOTOX, Placebo - Glabellar Lines | Phase 1 | Completed | 90 | 2022-08-30 | 2026-06-26 |
Safety and Efficacy of CKDB-501B in Subjects With Moderate-to-severe Glabellar Lines
CKDB-501B, Botox®50U - Glabellar Lines | Phase 1 | Completed | 30 | 2022-06-22 | 2022-11-17 |
Safety and Efficacy of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines
CKDB-501A, Botox® - Glabellar Lines | Phase 1 | Completed | 30 | 2022-02-15 | 2022-11-17 |
To Compare the Safety and Efficacy of "HG-102" With Botox® in the Improvement of Moderate to Severe Glabellar Lines.
Botulinum Toxin Type A Injection [Botox], Botulinum toxin type A injection [HG-102] - Glabellar Lines | Phase 1 | Completed | 38 | 2021-06-11 | 2022-05-24 |
The Safety and Efficacy Study of HU-014 Versus Botox® in Subject With Moderate to Severe Glabellar Lines
HU-014 Inj, Botox Inj - Glabellar Lines | Phase 1 / Phase 2 | Completed | 57 | 2016-09-01 | 2018-04-12 |
Interventions
Botulinum Toxins, Type A (6)
Sponsors
AbbVie (3) · CKD Bio Corporation (2) · Daewoong Pharmaceutical Co. LTD. (1) · Hugel (1) · Huons Co., Ltd. (1)
Countries
South Korea (5) · United States (3)
Top investigators
Beom Joon Kim, MD, Ph.D (1)